LO STROKE: TERAPIA INTERVENTISTICA E MODELLI ORGANIZZATIVI

San Benedetto del Tronto **28 - 29 Ottobre 2016** Aula Magna Ospedale del So<u>ccorso</u>

LE NUOVE FRONTIERE **DELL'ICTUS:** DALLA TROMBOLISI **SISTEMICA ALLA TERAPIA** INTERVENTISTICA LOCALEELA EMIEDICINA

nterdisciplinare


Trattamento endovascolare dell'ictus ischemico cerebrale in fase acuta

RELAZIONE FARMACI e DEVICE Nelle COMPLICANZE EMORRAGICHE

Salvatore Mangiafico Interventistica Neurovascolare A.O,U Careggi Firenze




Treatment modality





Combined treatment



Does it make sense to speak about drugs when all endovascular treatments are based on «mechanical» procedures?

Yes .. for two reasons

- The pharmacologic action (anticoagulant, fibrionolityc or antiaggregant) will go on after the recanalization of the occluded artery and it will extend differently during the phase of the cerebral reperfusion.
- During the immediate recanalization , a modification of the coagulative and platelet setting may increase the natural risk of hemorrhagic conversion

To reduce the hemorragic conversion it is important

1) to know the pharmaco dynamic and effects of the drugs on board at the moment of the endovascilar interventison

2) to definy the hemoragic profile of each patients

To reduce the hemorragic conversion it is important

1) to know the pharmaco dynamic and pharmacological effects of the drugs on board at the moment of the endovascilar interventison

HeparineFibrinolyticsAntiplatelet

Action on coagulationAction on microcirculationAction on BBE

• Fibrinolytics work slowly (UK, rTPA)



- Could be accompained by procoagulant activity (retro-thrombosis)
- Not very efficient on microcirculation: (local PAI-1 activation)
- May induce pro-inflammatory response if administrated too late


Resistance to fibrinolytics

During fibrinolysis (rtPA,UK) the clot releases **Fibrinogen Trombine -Fragments** Resistent to AT III (heparin) that activate the coaugulation cascade and PTL (fbg-Fibrina), with reorganization of the thrombus




Retrothrombosis

- Platelet's activation
- New thrombin generation
- New production of PAI-1
- Thrombin binding to the thrombus increases the *reaction* of fibrinogen to fibrin!



Pleiotropic actions of tPA




Heparine

- Heparine reduces the production of thrombine and the platelets activation
- Stops generation of a new fresh clot
- It is useful to avoid the progression of thrombosis and re-occlusion of a partially re-opened artery (retrothrombosis)

Increases the recanalization rate after IA fibrinolisys

Administration of Heparin at high dosage * and fibrinolytics increases bleeding risk (SIH)



* High dose:100 IU/kg bolus,1000IU /h x 4h

Hemorrage vs heparine

Heparine		Ν	Hemorr 24h	symptom	Hemorr 90 days	Hemorr symptom
High	proUK	11	72%	27%	72%	27.3%
	Placeb	5	20%	20%	40%	20%
Low	Pro-uk	15	20%	6.7%	33%	6.7%
	placeb	9	0%	0	33%	11.1%
Total	prouk	26	42,3%	15.4%	50%	15.4 %
	placeb	14	7%	7.1%	35.7%	14.3%

G.J del Zoppo "Proact :a phase II randomized Trial of Recombinant Pro-Urokinase by Direct Arterial Delivery in acute Middle Cerebral Artery Stroke (**Stroke,1998;29:4-11**)


• No Heparine infusion for 24 h after IAT (except patients with on-going AF and atrial thrombus)

Take home message

 The i.v. administration of heparine during the procedures of thrombectomy should be minimised

(either Guiding Catheter Flushed with 5000 UI in 1 L or bolus of 2000 UI at the beginning of the procedure

GPIIbIIIa inhibitors




GP IIb/IIIA receptor inhibitors

Reduce new clot generation blocking the PTL-FBN aggregation Increase the efficacy of IA thrombolysis (de-thrombosis): Reduce local production of PAI-1 Reduce changing in PTL Phosfolipid membrane :cofactor for thrombine production

Platelet disaggregation Enhancement of clot lysis


Increased recanalization rate reduced distal embolization



Viscosity reduction
Decrease of endothelial PAI-1 release
Inhibition of PTL/PMN interactions


Effect on patency of microcirculation of the Infarcted zone

Early platelet inhibition - Pharmacokinetics of Tirofiban -



Schneider, Am J Card 2003

Antagonists of the Gp IIb/IIIa farmacokinetics



Mousa et al. Drugs Future 1996;21: 1141-54

Gp IIb-IIIa Inhibitors

Cardiologic Protocol

- ABICIXIMAB (Reopro) :
- 025,mg/Kg rapid bolus (1min.) followed by IV continous infusion (0,125 microgr./Kg/min for 12 h post-Procedure.
- EPTIFIBATIDE (Integrilin):
- double IV bolus of 180-microg/Kg after 10 min + IV infusion of 2microg/Kg/min.for 18-24 h.
- TIROFIBAN (Aggrastat):
- IV bolus di 10 microg/Kg in 3 min.+ infusion 0,15 microg/Kg/min. per 18-24 h.

Normalization of bleeding time: 3-4 hours after end of IV infusion of INTEGRILIN and AGROSTAT,12h end of REOPRO infusion

Neuro-interventional protocol IV Bolus of Tirofiban (2/3 total dose) in 3 min IV infusion (1/2 dose depending on weight no longer than 6 hours) Use only in case of stent deplyment

To reduce the hemorragic conversion it is important

2) to definy the hemoragic profile of each patients

To reduce the hemorragic conversion it is important

2) to definy the hemoragic profile of each patients

Indivdual factors

(microcirculation leuocoaraiosis, anticogulants INR)

Age, Hypertension

Perfusional profile


The grade of cerebral hypoperfusion and the status of the microcirculation at the moment of the recanalization

Cerebral hypoperfusion and hemorrhagic risk

- Patients with severe cerebral hypoperfusion may more easily associated with hemorrhagic conversion (symptomatic hemorrhage) following recanalization
- The hemorrhagic areas are localised within or at the periphery of the ischemic lesion and are realted to the development of the ischemia
- The hemorrhagic areas show an intense enhancement or contrast pooling after endovascular procedure, secondary to the rupture of the BEE



The **perfusional profile** of a patient is linked to the efficacy of the retrograde reperfusion through the microcirculation supported by pial anastomoses or the polygone of Willis



Site of occlusion


Effectiveness of the collateral circulation

Correlation with core extension


Three different types of perfusional profiles

Type A: good collaterals


Type B: Poor collaterals




Type c: absent collaterals



acute





Cerebral Hypoperfusion (occlusion and collateral circulation)

> endotelial activation procoagluant reaction Deposit of fibrin in situ

Endotelial Pro Inflammatory Reaction Rupture of BBE

Three different types of perfusional profiles

Type A: good collaterals



The retrograde perfusion by the microcirculation is effective to contrast the progression of the ischemic core and to preserve the stability of the BBB


The expansion of the ischemic core is probably slow (almost time-independent), <u>possible</u> <u>treatment even beyond 6 hours</u>


The alterations of the BBB are minimal


<u>The risk of hemorrhagic conversion after</u> <u>efficient reperfusion is minimal</u>

A good collateral perfusion (CCS 5-4) is a Predictor of good clinical outcome and low Risk of hemorrhagic conversion

acute









mRS 0 3 months FU


- M, 51 y.o
- h 11.15 aphasia, right hemiparesis
- P.S.: NIHSS 9, full-dose i.v. t-PA, minimal clinical improvement (NIHSS 8) after 40 min. Hospitalised in Stroke Unit
- h 17:10 Clinical deterioration with right hemiplegia and aphasia
















Aggrastat 21 cc i.v.+ 10 cc i.a.



Final DSA, deployed stent








ICA-M1 occlusion, CCS4







1.20/09/2011

26/09/2011 11:5 47 49 SeDt 26/09/2011 SeTm 5 47 43

Thrombectomy: recanalization TICI 2b








Pharmacological profile

- In patients with small score, wide mismatch and good collaterals it is possible to administer fibrinolytics (i.v. rT-PA) or Antiplatelets without increasing th risk of hemorragic transformation
- Platelet inhibitors in case of extra or intracranial stenting do not increase the hemorrhagic risk, even after i.v. t-PA


Three different types of perfusional profiles








The retrograde perfusion by the microcirculation is poorly effective to slower the evolution of the ischemic core, the expansion of the core is rapid and the integrity of the BBE is not assured




The expansion of the ischemic core is probably rapid (timedependent)

BEE alterations are early


Risk of hemorrhage has to be considered more carefully






• Pial collaterals do not supply all the cortical territory fo the MCA

- Cortical avascular areas
- •Insular arteries visualised only in late venous phase *
- •Suspended artery **






Pharmacological profile

- In patients with wide core, small mismatch and poor collaterals, the loco-regional administration of fibrinolytics is contraindicated
- The hemorragic risk is increased if the patient received i.v. rt-PA
- Platelet inhibitors in case of extra or intracranial stenting is contraindicated because the hemorrhagic risk is increased, particularly after i.v. t-PA


Type c: absent collaterals







- Collaterals do not supply the ischemic territory
- The extension of the ischemic core is rapidly at the maximum
- Any recanalization grade (partial or complete) will not modify the extension of the ischemic core
- Therapeutic window is closed


No indication to endovascular treatment







85 yo M 13.00 Left hemiplegia TC : Hyperdensity of MCA Time to groin ; h3.30 (16.














DSA: 4.5 h from onset Poor collaterals (CCSO) **Correlation with CT-P!**

Pharmacological profile

- In patients without mismatch and collaterals, the locoregional administration of fibrinolytics and platelet inhibitors is contraindicated
- The endovascular treatment should not be performed
- The hemorrhagic risk is increased if the patient received i.v. t-PA

THERAPEUTIC PROTOCOL

- After rt-PA i.v. and Thtombectomy no Anticoagulants and antiplatelets for 24 h
- <u>After carotid PTA</u>, only i.v. aspirine 500 mg ev from the day of the procedure
- After carotid PTA-Stenting or intracranial stenting:
- Aggrastat (Tirofiban) i.v. bolus 2/3 of the dose at the moment of the deployment
- Clopidogrel and ASA since the day after the procedure (If CT rules out BBB alterations or initial hemorrhagic transformation)

Medical therapy Post stenting in patients without systemic IV tPA

- No heparin for 24h
- Administration of IV tirofiban (½ dose in base PC/h) for six hours

only if control TC scan shows

- no hedema
- no pathological enhancement of Basal Ganglia only if DSA shows
- Good and efficient Collateral circulation before treatment
- a partial recanalization (TICI 2a- 3)
 only if TC Perfusion shows
 wide mismatch

Post stenting medical therapy in case of A. Carotid occlusion Previously treated wirh i.v. t-pa

Double platelet inibition (Clopidogrel and Aspirin) is given after 24 h from the end of intervention (after CT negative for hemorrhagic conversion) In case of altered BBE only aspirine (150 mg die) since normalization of BBE


In alternative, immediate PTA followed by PTAS (after 1 week) from clinical onset ONLY if ECHO doppler EXAMINATIONS show stability of the initial recanalization

The devices : action on the clot



- Mechanical Retraction Thrombectomy
- Thromboaspiration
- Mechanical Interaction with the clot
- Trapping
- Fragmentation

- Nature of the clot
- Extension of the clot
- Clot burden
- Localization of the clot (bifurcation)



Engineering of stentriever

Flow restoration (by-pass)

Wall apposition

- Radial Force
- Close cell
- Small cell area

Clot trapping

- Inhomogeneous cell design
- Small cell area
- Struts Orientation

Clot traction, Conformability

(clot fragmentation, vessel wall damage)

- Cell design: closed or Hybrid design, deformation
- Equilibrated radial force
- Spiral cell orientation
- Length of working zone
- Tapered (close) distal end

Technical features

Cell design

- Cell geometry and width
- Strut orientation
- Radial force
- Distal guide wire
- Distal end

Cell design, geometry and width:


- closed cells: increase stability, no deformation in curves
- <u>Variability</u> of cell design/area vary the force applied on the thrombus (linear proportion force applied-number of cells), <u>homogeneous</u> cell design/area: same force applied
- <u>Large</u> cells: increase stability; more trapping capabilities?
- Strut orientation
- <u>horizontal and thin (stent-like</u>) not designed for thrombectomy
- vertical arrangement could help clot-stent integration
- Helical/oblique arrangement could help clot retrieval

Technical features

- Cell design
- Cell geometry and width
- Strut orientation
- Radial force
- Distal guide wire
- Distal end


• Radial force:

- <u>High</u> radial force: immediate reopening of the vessel (temporary by pass) and may improve stent-clot interaction; <u>constant:</u> reduces vessel wall trauma
- Distal guide wire:
- May provide stability and help the positioning
- Risk of perforation
- Distal end:
- Closed: theoretical reduction of clot migration




STENTRIEVERS (Stent like retrievers)

- Stent-like structure
- Retrieval of the clot
- "Endovascular by-pass" effect with immediate flow restoration
- Mechanical action of clot fragmentation





M, 67 yo. Atrial Fibrillation H 13:15 left hemiplegia, confusion CT scan negative H 15:30 i.v. tPA (full dose) (NIHSS 18), No clinical improvement After 1 h H16:15 arrive at Angiosuite



Technique : thrombectomy (Mechanical Clot Disruption)

F, 70 y.o., left hemiparesis , dysarthria (NIHSS 16) Time of ischemia 5 h






Envoy 6F Prowler Select Plus Terumo .012 Solitaire 4x20



After positioning of the Solitaire



Watch and wait...


5 min control: Stent opened within the clot Control after other 5 min

10 min Time of Interaction stent clot




Immediately after retrieval


Final DSA (after 5 min.)



TC 24 h NIHSS 0 at the discharge

thrombus-aspiration (3 different techniques)





Proximal Thromboaspiration

Direct thrombus aspiration (ADAPT technique: removal through thrombo aspiration)

new technique utilizing a direct aspiration first pass technique with a large bore aspiration catheter as the primary method for vessel recanalization.

Int 6F

(0.88"-

а

0.016 inch Fathom microwire Velocity microcatheter 0.025 5 Max penumbra reperfusion catheter 5F neuron max


ORIGINAL RESEARCH


Initial clinical experience with the ADAPT technique: A direct aspiration first pass technique for stroke thrombectomy

Aquilla S Turk,¹ Alex Spiotta,² Don Frei,³ J Mocco,⁴ Blaise Baxter,⁵ David Fiorella,⁶ Adnan Siddiqui,⁷ Maxim Mokin,⁷ Michael Dewan,⁴ Henry Woo,⁶ Raymond Turner,² Harris Hawk,¹ Amrendra Miranpuri,¹ Imran Chaudry¹


F, 40 NIHSS22 Fibrinolisi i.v. Onset to groin: 5h15...









Exceptional Trackability









TTR 5h50 Time of procedure 35 min



Combination of thecniques




F, 34 yo X week of pregnacy GCS9






Onset to groin 4h45 min



Trevo Xp Provue + Revive IC Rimosso il microcatetere Pince tecnique

1 passage TTR: 5h 16 min of proceture , 5.6 min of Xray exposition , 24786 mGcm²



rationale use of device

- High clot burden (ACI + MCA occlusion) ADAPT technique first
- M1, M1-M2 BA : stetntriver with proximal thrombus aspiration first
- Distal occlusion (P2, P3 A2-A3, Cortical arteries) Thrombus aspiration First

Conclusion

- To treat stroke is not a matter of techniques
- To treat a stroke is a matter of understanding the clinical status, the perfusional profile, the collateral circulation, the clot stucture, the extension and localization of the occlusion
- All these are the points on the base of which it is possible to have a tailored and rationale approach to the stroke pathology

Trattamento endovascolare dell'ictus ischemico cerebrale in fase acuta

RELAZIONE FARMACI e DEVICE Nelle COMPLICANZE EMORRAGICHE

Salvatore Mangiafico Interventistica Neurovascolare A.O,U Careggi Firenze